Interest of Measuring P2X4 Receptors on Blood Monocytes as a Diagnostic Marker in Amyotrophic Lateral Sclerosis: P2X4 as a Diagnostic Biomarker for ALS
University Hospital, Bordeaux
50 participants
Jan 15, 2026
INTERVENTIONAL
Conditions
Summary
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease and is characterized by the degeneration of motor neurons leading to progressive paralysis and death within 3 to 5 years after diagnosis. To date, no key mechanism had been identified. Our associated laboratory has identified the P2X4 purinergic pathway that appears to be involved in the pathogenesis of ALS. Our goal is to verify these results at the human level in order to have a proof of concept of P2X4's role as a biomarker of the disease.
Eligibility
Inclusion Criteria4
- For ALS group: Person presenting a probable or confirmed diagnosis of ALS according to the criteria of EI Escorial.
- Adult.
- Person affiliated or beneficiary of a social security scheme.
- Free, informed and written consent signed by the participant or by a third person (in case of physical incapacity of the participant), after information on the study.
Exclusion Criteria4
- People undergoing immunosuppressive or corticosteroid treatments.
- Participation in a research protocol with an experimental treatment.
- People placed under guardianship, curatorship or legal protection.
- For healthy volunteer, people directly related to the patient (siblings, descendants and ancestry).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This is an interventional study designed to assay P2X4 receptors in blood samples from ALS patients and healthy volunteers by comparing the mean levels of P2X4 expression.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07091799